Herceptin Project
The Herceptin project was launched in 2005 as a clinical registry of patients with breast carcinoma, who have been treated with Herceptin. At the start of the project, only patients with metastatic breast carcinoma were included in the study. Since 2006, however, Herceptin can be used to treat breast carcinoma of less advanced stages, and patients treated with Herceptin in adjuvant therapy are included as well. The project is focused on the collection of patients´ epidemiological and clinical data in order to assess treatment safety and effectiveness, monitoring the treatment response and defined survival parameters. In December 2007, the Herceptin registry contained more than 2000 records of patients treated with Herceptin, which is a clinically significant dataset from the population point of view.

Breast carcinoma

Breast carcinoma is the most frequent cancer diagnose in women all over the world. This applies also for the Czech Republic, where breast carcinoma affects almost 6000 women of all age groups every year (read more on breast carcinoma incidence in the Czech Republic). Despite the high incidence of this disease, however, the number of successfully treated patients is ever increasing. A targeted biological therapy is very promising, in the sense that it can trace cancer cells, stop their growth and potentially destroy them. This could be a breakthrough not only in the treatment of breast carcinoma, but in other cancer diagnoses as well. Biological therapy involves drugs such as Herceptin, which effectively helps to treat one type of breast carcinoma, characterized with an increased expression of epidermal growth factor 2 (gene HER2). In this HER2-positive type of cancer, Herceptin specifically blocks the HER2 receptor, which finally stops tumour growth or even leads to regression of the tumour.

Monitoring parametric profiles in breast carcinoma patients treated with Herceptin provides an unique opportunity to describe the epidemiological situation of HER2-positive patients in the Czech Republic. These data can be effectively used not only to evaluate risk factors and overall survival, but also to make economical predictions, e.g. to estimate the costs of anticancer therapy. Here are main objectives of the Herceptin project:

Primary objectives of the project:

  • Monitoring the total number of patients treated with Herceptin in the Czech Republic.
  • Assessing the treatment safety of Herceptin.
  • Assessing the treatment effectiveness of Herceptin.

Secondary objectives of the project:

  • Analysis of patients' survival in relation to monitored clinical factors.
  • Analysis of data from patients treated with Herceptin in relation to reference population data of the Czech Republic.